Showing 481 - 500 results of 53,548 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (mean decrease)) ))', query time: 1.19s Refine Results
  1. 481

    Decrease in Vitamin D Status in the Greenlandic Adult Population from 1987–2010 by Nina O. Nielsen (490187)

    Published 2014
    “…In all age-groups it decreased from 1987 to 2005–2010 (32%–58%). Low 25(OH)D3 concentrations (<50 nmol/L) were present in 77% of the 18–29 year old and decreased with age. …”
  2. 482

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
  3. 483
  4. 484
  5. 485
  6. 486

    PLD inhibitors decrease PLD2 expression in foci of lungs following xenotransplantation. by Karen M. Henkels (3350273)

    Published 2016
    “…(<b>B-D</b>) Lung sections from non-xenographed controls. (<b>B</b>) PLD2-FITC staining only. …”
  7. 487

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  8. 488

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  9. 489
  10. 490
  11. 491
  12. 492
  13. 493
  14. 494

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  15. 495
  16. 496
  17. 497
  18. 498
  19. 499

    Treatment with anti-JAM-C antibody decreases the severity of antigen-induced arthritis by Gaby Palmer (636)

    Published 2011
    “…Results are expressed as the ratio of technetium-99m (Tc) uptake in the arthritic over the non-inflamed knee. The mean ± standard error of the mean (SEM) of the ratios is shown for anti-JAM-C antibody-treated (= 10 for days 1 and 3, = 6 for day 7; black symbols) and isotype-matched control antibody-treated (= 10 for days 1 and 3, = 5 for day 7; open symbols) mice. …”
  20. 500